Carglumic acid is formed from N-acetyl glutamate and aids in ammonia elimination and detoxification by activating the first enzyme in the urea cycle. This medicine is particularly useful in the treatment of rare disorders such as propionic academia and methyl-malonic academia, which are autosomal recessive and frequently necessitate lifetime medical therapy to preserve normal health.
According to SPER market research, ‘Global Carglumic Acid Market Size- By Dosage Form, By Distribution Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2034’ state that the Global Carglumic Acid Market is predicted to reach 309.94 million by 2034 with a CAGR of 7.69%.
Drivers:
The Carglumic Acid Market is growing due to the rising number of urea cycle disorders, which increases the demand for treatments. More awareness of genetic disorders is leading to earlier diagnoses and more use of carglumic acid. Advancements in healthcare and supportive regulations are also improving access to treatments, boosting the market. Opportunities exist for expanding carglumic acid applications beyond rare diseases, and developing new dosage forms or delivery methods could increase market reach.
Request a Free Sample Report: https://www.sperresearch.com/report-store/carglumic-acid-market?sample=1
Restraints:
The use of carglumic acid has been restricted by the high cost of acquiring raw materials, the increased capital required for processing the finished product, and certain negative consequences linked to carglumic acid treatments. Furthermore, rising research and development costs, combined with the high cost of medicine, have increased the cost of overall production, prompting customers to seek alternatives. Furthermore, the shelf life of the drug carglumic acid is shorter than a month, thus bottles must be discarded after opening. It is anticipated that these challenges will hinder the growth of carglumic acid sales over the forecast period.
North America led the market in 2024, driven by a rise in metabolic diseases and a strong presence of industry players. Sedentary lifestyles and high alcohol consumption contribute to disorders like cirrhosis and hyperammonemia, increasing product demand. Meanwhile, the Asia-Pacific region is expected to grow the fastest due to greater awareness of metabolic diseases, an aging population prone to chronic illnesses, and more government initiatives supporting the market. Some of the key market players are Apothecon Pharmaceuticals Pvt. Ltd, Recordati Rare Diseases Inc, Manus Aktteva Biopharma LLP, Dipharma Francis S.r.l, NURAY CHEMICALS, NOVITIUM PHARMA LLC, and others.
For More Information, refer to below link: –
Related Reports:
Transthyretin Amyloidosis Treatment Market Growth
Follow Us –
LinkedIn | Instagram | Facebook | Twitter
Contact Us:
Sara Lopes, Business Consultant — USA
SPER Market Research
enquiries@sperresearch.com
+1–347–460–2899